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Literature reports increased FDG nodal uptake in HIV-positive patients. Our aim is to identify differences in pre-
sentation and characteristics of FDG-avid lymph nodes between HIV-positive and HIV-negative locally advanced
cervical cancer (LACC) patients in our clinical setting. We evaluated 250 pre-treatment 18F-FDG PET/CT imaging
studies from women screened for a phase III randomised controlled trial investigating modulated electro-hyperther-
mia as a radiosensitiser (Ethics approval: M120477). The number of nodes; size; maximum standardised uptake
value (SUVmax); symmetry; and relationship between nodal size and SUVmax uptake, were assessed by region
and by HIV status. In total, 1314 nodes with a SUVmax ≥ 2.5 were visualised. Of 128(51%) HIV-positive partic-
ipants, 82% were on antiretroviral therapy (ART) and 10 had a CD4 count <200 cells/mL. Overall pattern of pre-
sentation and nodal characteristics were similar between HIV-positive and -negative groups and the uniformity in
presentation of the nodes draining the cervix strongly suggests these nodes may be attributed to malignancy
rather than HIV infection. Novel findings: HIV infection is associated with: >four nodes visualised in the neck,
symmetrical inguinal lymph nodes, increased rates of supraclavicular node visualisation; FDG-avid axillary nodes
were more common, but not exclusive, in HIV-positive participants. 18F-FDG PET/CT is a reliable staging method
for LACC in HIV-positive patients who are not in acute stages of HIV infection, have a CD4 count >200 cells/mL,
and/or are on ART and there is a potential risk of underestimating metastatic spread by attributing increased
nodal metabolic activity to HIV infection in these patients.
INTRODUCTION
Position emission tomography (PET) is an imaging modality that
uses a tomographic technique to measure the 3-dimensional dis-
tribution of positron-emitting labeled radiotracers. 18Flourine-
labeled glucose (18-fluoro-2-deoxyglucose; 18F-FDG) is the most
commonly used tracer for PET studies. Most cancers characteris-
tically have increased utilization of glucose, upregulation of glu-
cose transporters, and consequently an increased uptake of
glucose analogue FDG on PET studies. This allows for the nonin-
vasive quantification of tumor metabolic activity, measured by
the standardized uptake value (SUV) of FDG by the tumor
compared with the FDG uptake value of background tissues. The
addition of computed tomography (CT) allows the morphological
evaluation of the tumor to improve the accuracy of the size and
localization, combined with the metabolic measurement on the
PET images (1).
One advantage of 18F-FDG PET/CT is its ability to detect
metabolic changes before anatomical changes occur, making it
more sensitive to the nodal disease status of patients (2, 3). In
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IMAGE REPORTS
the developed world, several studies have assessed the role of
18F-FDG PET/CT in the staging and management of patients
with locally advanced cervical cancer (LACC), and results from
18F-FDG PET/CT scans can provide important prognostic infor-
mation for these patients with cervical cancer (4). The staging of
cervical cancer is based on the FIGO (International Federation
of Gynecology and Obstetrics) classification, which is a clinical
staging system involving a thorough clinical examination and
anatomical imaging. In a resource-constrained setting, a chest x-
ray, abdominal ultrasonography, and cystoscopy are routinely
performed on patients with cervical cancer with further investi-
gations considered on a case-by-case basis, and depending on
resources and availability (5).
Morkel et al. reported that the addition of 18F-FDG PET/CT
to the initial screening protocols for patients with FIGO stage
IIIB cervical cancer revealed relevant disease information that
was missed by clinical staging and other imaging techniques.
The information gathered from the 18F-FDG PET/CT resulted in a
change in treatment protocols in a significant number of patients
with cervical cancer (5). In a study by Kidd et al., 53% of the 234
patients with cervical cancer (FIGO stage IB1–IVA), had FDG-
avid lymph nodes on 18F-FDG PET/CT scans, with nodes visual-
ized as high as the supraclavicular region. Lymph node status as
visualized on the 18F-FDG PET/CT scans had a significant effect
on patient outcomes, and the presence and number of lymph
node metastases are known prognostic factors (6, 7). The sensi-
tivity of the PET/CT studies depends on the stage of disease, with
limited benefit of the use of 18F-FDG PET/CT scans seen in early
stages of cervical cancer (8-10). The typical metastatic pattern
for cervical cancer is from the nodes directly draining the cervix
(parametrium and paracervix), to the external iliac, internal iliac,
obturator, and mesorectum groups (sometimes referred to as level
one), to the common iliac and presacral groups (or level two
groups), to para-aortic nodes (level three) (11-13).
A well-known challenge regarding the interpretation of
18F-FDG PET/CT scans is the risk of false-positive results in
patients with acute infections or inflammatory conditions (14).
Activated inflammatory cells, such as macrophages, lympho-
cytes, neutrophil granulocytes, and fibroblasts, have been shown
to avidly take up FDG, resulting in an FDG uptake that is higher
than the background uptake (15). The gradual decrease in CD4
cells of human immunodeficiency virus (HIV)-1-infected individ-
uals is associated with a decline in the function of patient’s
immune system. The homing theory suggests that the homing of
HIV-infected CD4 cells from the blood to the lymph nodes where
they undergo apoptosis is a possible cause for the decrease in
CD4 counts (16, 17). This correlates with generalized lymphade-
nopathy typically seen in HIV-infected patients.
Studies have shown the importance of taking the HIV status
of the patient into account when interpreting the results of 18F-
FDG PET/CT images of patients with cancer. Morkel et al. found
a significant inverse relationship between the CD4 count of HIV-
positive patients and the mean SUV of their lymph nodes (5), and
another study found that HIV-positive patients with high viral
load levels may have benign hypermetabolic foci visualized on
18F-FDG PET/CT images (18). This may result in false-positive
interpretations of malignancy. Increased FDG uptake of the
lymphoid tissue is seen in the head and neck region during acute
HIV infection, in the peripheral nodes (including the axillary and
inguinal nodes) during chronic infection, and in the abdominal
lymph nodes during late stages of HIV infection (18-20). A
detailed study by Brust et al. showed that healthy HIV-infected
individuals with suppressed viral loads, and their HIV-negative
counterparts, had little to no FDG uptake in lymph nodes; how-
ever, HIV-positive patients with high viral loads and advanced
HIV infection had increased FDG uptake in the peripheral lymph
nodes (21).
To the best of our knowledge, there are no larger studies
investigating the nodal characteristics and distribution patterns
of HIV-positive, compared to HIV-negative, patients with LACC
in a resource-constrained setting. In this paper, we report on the
results of 18F-FDG PET/CT images from participants enrolled in
an ongoing phase III randomized controlled trial on the effects of
the addition of modulated electro-hyperthermia to chemoradia-
tion protocols in South Africa. We aim to identify differences in
the characteristics of positive lymph nodes between HIV-positive
and HIV-negative LACC participants. This may assist in more
accurate reporting and staging of cervical cancer on 18F-FDG
PET/CT studies in geographic areas with a high incidence of HIV
infection.
MATERIALS AND METHODS
The data for this analysis are part of a phase III randomized con-
trolled trial investigating the addition of modulated electrohy-
perthermia to chemoradiotherapy for the treatment of patients
with LACC. The trial is being conducted in our local academic
hospital by the Department of Radiation Sciences of the
University of the Witwatersrand, Johannesburg, South Africa.
All procedures performed in studies involving human partici-
pants were in accordance with the ethical standards of the insti-
tutional/national research committee (Human Research Ethics
Committee approval: M120477) and the 1964 Helsinki declara-
tion and its later amendments or comparable ethical standards.
The trial was registered on the South African National Clinical
Trials Register before recruitment started (ID: 3012) and at
ClincialTrials.gov ID: NCT03332069. Informed consent was
obtained from all individual participants included in the study.
Eligibility
As part of the screening evaluation for the trial protocol, poten-
tial participants had additional hematological investigations
including HIV tests and CD4 count, and they underwent 18F-FDG
PET/CT imaging studies before randomization, but only after
signing the informed consent.
Patients were considered eligible for screening for the trial
and were therefore found eligible for this analysis if they
were>18 years old, with histologically confirmed squamous cell
carcinoma of the cervix, FIGO stage IIB (with distal involvement
of the parametrium) to IIIB (staged clinically), creatinine clear-
ance of >60 mL/min, reported knowing their HIV-status, did not
have any AIDS-defining illnesses except for cervical cancer,
were deemed fit for treatment with radical intent, and had a life
expectancy of>12 months.
Once the screening process was complete, exclusion criteria
for randomization for the trial based on the screening results
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included a CD4 count of <200 cells/mL if HIV-positive, visceral
metastatic disease, bilateral hydronephrosis, or fistulas visualized
on 18F-FDG PET/CT scans.
In total, 270 participants were screened, 250 of whom under-
went pretreatment 18F-FDG PET/CT imaging studies, and 210
were deemed eligible for trial and were randomized for treat-
ment. For the purpose of this report, we evaluated all 250 of the
18F-FDG PET/CT imaging studies conducted as part of the
screening process.
Patient Preparation and Imaging Protocol
Participants were prepared for the 18F-FDG PET/CT scans accord-
ing to department standard protocols. Plasma glucose was
checked before the scan, and hydration was administered to par-
ticipants whose plasma glucose levels were ≥11mmol/L or more
to lower glucose levels and minimize the interference by high
glucose (1). The PET/CT study was rescheduled if the plasma glu-
cose could not be adequately lowered. Our protocol aimed for an
uptake period of 61 h between injection and scanning (1)
depending on the logistics. Participants were injected with a
mean of 378.51 MBq (minimum, 135.79 MBq; maximum, 462.5
MBq) of FDG. The participants’ mean plasma glucose level was
5.7mmol/L (minimum, 3.7mmol/L; maximum, 12.2mmol/L),
and there was a mean interval of 66.5min (minimum, 50; maxi-
mum, 125) between injection time and acquisition of body
image.
The scanning protocol begins with a scout image, followed
by a low-dose CT image (with intravenous contrast when not
contraindicated) of the whole body. This was followed by
“whole-body” PET imaging in 7 bed positions, 3min per bed,
starting from mid-thigh to the base of the skull. A diagnostic CT
of the chest was then performed. The 18F-FDG PET/CT scans
were obtained using a Siemens BiographTM 40 PET/CT (Siemens
Healthcare GmbH; Erlangen, Germany).
Nodal Analysis
The nodal characteristics assessed included number of nodes and
their largest diameter on CT scans, uptake assessed by measured
maximum SUV (SUVmax), symmetry, and relationship between
nodal size and SUVmax uptake. SUVmax ≥ 2.5 was used as a
cutoff for active nodes. Patterns were compared between differ-
ent anatomical regions that included the pelvis, abdomen,
thorax, and head and neck. First, the characteristics of all of the
nodes were analyzed depending on whether the node appeared
in the HIV-negative or -positive participants (nodal analysis).
Then the participants in each group (HIV-positive and HIV-nega-
tive) were assessed, and the characteristics of their nodes were
compared (participant analysis). A subgroup analysis of specific
node groups responsible for the drainage of the cervix and nodes
known to be positive in HIV infection was conducted.
Statistics
Frequencies and percentages were calculated, and we used chi-
square frequency tables, unpaired t test, linear regression and
logistic regression models to measure associations, differences,
and odds ratios. STATA 13.0 Statistics software program (Stata
Corporation, College Station, TX) was used to analyze the data.
Funding
This study was funded by the National Research Foundation of
South Africa (TP12082710852). 18F-FDG was supplied at a dis-
counted rate by Radioisotopes SOC Ltd. NTP Radioisotopes SOC Ltd
is a state owned company and a subsidiary of the South African
Nuclear Energy Corporation. The company manufactures and sup-
plies radioisotopes. Funding sources had no role in study design,
implementation, data collection, and data analysis or development/
review of the manuscript.
RESULTS
Participant characteristics are listed in Table 1. Majority of the par-
ticipants were African (92%); 128 (51%) were HIV-positive, 119
(82%) of whom were on antiretroviral therapy (ART) at the time of
the scan. The median CD4 count was 506.5 cells/mL (range, 95–
1524 cells/mL), and 10 participants had a CD4 count<200 cells/mL.
Overall Nodal Analysis
In total, 2299 nodes were visualized, 1314 of which had SUVmax
≥ 2.5 and were included in the analysis (HIV-positive, 713 [54%];
HIV-negative, 601[46%]). A summary of the number of nodes
per region, and of the HIV status of the participant in which the
node was visualized, can be seen in Table 2.
SUVmax Analysis by Region. Overall, the mean SUVmax was
significantly higher in the pelvis and the abdomen compared
with the head and neck region (P< .001) and thorax (P< .001).
However the difference in SUVmax between the abdominal and
pelvic nodes was not significant (P= .397). The mean SUVmax
was the highest in the pelvis, and this was significantly higher
than that in any other region (P< .001).
SUV and HIV Status. When considering all nodes, in a multi-
variate logistic regression analysis, a higher SUVmax was a pre-
dictor of the HIV status of the participants in which the node was
visualized (OR, 0.97; P= .022; 95% CI, 0.945–0.996). However
when considering the nodes by region, the abdomen was the
only region in which the SUVmax of the nodes was predictive of
the HIV status of the participants (OR, 0.92; P= .006; 95% CI,
0.86–0.98). When considering the SUVmax of all of the visualized
lymph nodes, grouped into bins of 10 starting from 3, HIV-nega-
tive participants were more likely to have SUVmax of between 3
and 23 and SUVmax > 23 is associated with an HIV-positive sta-
tus (chi-square: P= .028). The association was however not signifi-
cant in a chi-square analysis of each region. In HIV-positive
participants, the relationship between SUVmax and CD4 count
was not significant (P= .131; 95% CI,0.003 to 0.0003).
Size Analysis by Region. The largest nodes were seen in the pel-
vis, and the difference in sizes between the pelvic and abdominal
nodes was significant (P< .0001). The lymph nodes in the abdo-
men were significantly larger than the nodes of the thorax
(P= .0047) and those in the head and neck (P< .0001).
Size and HIV Status.When considering the size of the nodes (in
centimeters), grouped into 0.5-cm bins, the only significant finding
was that the nodes from the abdomen of HIV-positive participants
are more likely to be <1.49cm (106 out of 146 vs 80 out of 142),
and the nodes from HIV-negative participants are more likely to be
1.49cm–2.49cm (51 out of 145 vs 28 out of 142; chi-square:
P= .027). In a logistic regression analysis, lymph node size was not
predictive of the HIV status; however, the increased size was
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significantly associated with reduced CD4 counts in HIV-positive
participants (coefficient, –21.34; P= .033; 95% CI, 40.94 to 1.75):
Supplemental Image 3 is of the participant (42) who was HIV-
positive and had the highest SUVmeasured in a lymph node (54.2).
Relationship Between SUV and Size. The mean size of the
visualized nodes was 1.55 cm (standard deviation [SD], 0.93; mini-
mum, 0.5 cm; maximum, 14.2 cm chain of nodes) and the mean
SUVmax was 6.43 (SD, 4.87; minimum, 2.5; maximum, 54.21).
There is a moderately strong (r=0.5) and significant (P< .001)
positive relationship between the overall SUVmax and node diam-
eter. This relationship was significant for each region, regardless
of the HIV status, when analyzed independent of the participants
and when analyzed per participant (Figure 1).
Analysis of LymphNodesWithin Participants (Participant
Analysis)
In paired t-test analyses, the maximum size of the nodes, the maxi-
mum SUVmax of the nodes, and the number of nodes overall and
by region were assessed in each participant. There were no signifi-
cant differences in the numbers of nodes in HIV-positive partici-
pants compared with HIV-negative participants (P> .05). These
results are summarized in Table 3 and represented graphically in
online supplemental Images 1, 2, and 4. To determine if there is any
association between HIV status and a specific size or SUVmax,
nodes were organized into bins and frequency tables were
Table 1. Participant Characteristicsa E
Overall HIV-Positive HIV-Negative
P Valuen [%] n [%] n [%]
250 128 [51%] 122 [49%]
ECOG Performance Status
0 10 [4%] 5 [3.9%] 5 [4%]
x2: P=0.3821 238 [95%] 121 [94.5%] 117 [96%]
2 2 [1%] 2 [1.6%] 0 [0%]
Race
African 229 [92%] 123 [96%] 106 [87%]
x2: P=0.004Caucasian 10 [4%] 0 [0%] 10 [8%]
Other 11 [4%] 5 [4%] 6 [5%]
Age (years)
Median 47.7 43.2 52.5
t-test: p<0.0001Range 25.9–72.7 26.6–62.4 25.9–72.7
BMI
Median 26 24 28




Abbreviations: BMI: Body Mass Index; HIV: Human Immunodeficiency Virus; ECOG: Eastern Cooperative Oncology Group.
a Characteristics of the participants in the study: ECOG performance was similar in both groups; there were significantly more African HIV-positive par-
ticipants and more Caucasian HIV-negative participants; the mean age and BMI was significantly higher in the HIV-negative participants.
Table 2. Number of Nodes per Region and
the HIV Status of the Participant in Which the
Nodes Were Visualizeda
Total HIV-Positive HIV-Negative
Head and Neck 225 139 [62%] 86 [38%]
Thorax 210 115 [55%] 96 [45%]
Abdomen 293 149 [51%] 144 [49%]
Pelvis 586 310 [53%] 276 [47%]
Total number of nodes 1314 713 [54%] 601 [46%]
a Overall there were more nodes visualized in HIV-positive participants,
with the largest difference in the number of nodes between HIV-positive
and -negative participants seen in the head and neck region.
Figure 1. Linear relationship between the
SUVmax and size of the lymph nodes in HIV-
positive and -negative participants. A signifi-
cant (P< .001) positive association is seen
between the SUVmax of the lymph node and
the diameter of the lymph node, and this rela-
tionship is independent of HIV status.
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generated. No significant association was seen when looking at par-
ticipants’ maximum or mean size or SUVmax. The only significant
association between HIV status and number of lymph nodes in par-
ticipant was seen in the head and neck region, where >4 nodes are
more strongly associated with HIV infection (chi-square: P= .004).
Subgroup Analysis
A subgroup analysis of specific lymph node groups known to be
positive on 18F-FDG PET/CT in HIV-positive patients to deter-
mine whether, in our sample, there is a risk of understaging of
the cervical cancer by attributing positive nodes to HIV-infection
rather than malignancy was conducted.
Head and Neck Nodes (Known to Be Positive in Early HIV
Infection). Of specific interest in the head and neck region was
the significantly higher number of supraclavicular nodes
visualized in HIV-positive participants (mean, 0.15; SD, 0.454;
95% CI, 0.069–0.228) compared with the number of those in
HIV-negative participants (mean, 0.05; SD, 0.217; 95% CI, 0.01–
0.09) (P= .0296). Posterior cervical nodes were also visualized
significantly more (P= .0037) in HIV-positive participants (mean,
0.21; SD, 0.053; 95% CI, 0.107–0.315) than in HIV-negative par-
ticipants (mean, 0.04; SD, 0.022; 95% CI, 0.002–0.084). Online
supplemental Images 5a and 5b are of the HIV-positive (5a) and
HIV-negative (5b) participants with the highest number of lymph
nodes visualized in the head and neck region.
Axillary Nodes (Known to Be Positive in Chronic HIV
Infection). Seven out of 122 (6%) HIV-negative and 29 out of
128 (23%) HIV-positive participants presented with axillary
nodes visualized on 18F-FDG PET/CT scans. In a logistic regres-
sion analysis, each increase in the number of axillary nodes is
Table 3. Comparison of Means Summary of Nodes Per Participanta E
HIV-Positive (n =128) HIV-Negative (n=122)
Mean SD Mean SD t-test
Head and Neck n=51 [40%] n=43 [35%] P=0.453
No Nodes Per participant 1.09 1.88 0.71 1.31 P=0.0652
SUVmax 4.48 2.05 4.68 2.86 P=0.6869
Diameter 1.17 0.29 1.21 0.36 P=0.5964
Highest SUVmax 5.63 4.07 5.69 4.60 P=0.9442
Maximum Diameter 1.41 0.55 1.34 0.54 P=0.5256
Thorax n=54 [42%] n=44 [36%] P=0.322
No Nodes Per participant 0.90 1.35 0.78 1.31 P=0.4774
SUVmax 5.14 3.09 4.93 3.25 P=0.7473
Diameter 1.42 0.66 1.29 0.47 P=0.2707
Highest SUVmax 5.86 3.65 5.70 3.98 P=0.8300
Maximum Diameter 1.74 1.85 1.49 0.69 P=0.4017
Abdomen n=68 [53%] n=62 [51%] P=0.715
No Nodes Per participant 1.16 1.44 1.18 1.55 P=0.9315
SUVmax 6.65 4.50 7.67 4.38 P=0.1940
Diameter 1.45 0.69 1.55 0.85 P=0.4334
Highest SUVmax 7.85 5.26 9.11 5.35 P=1.1779
Maximum Diameter 1.77 1.21 1.89 1.23 P=0.5763
Pelvis n=99 [77%] n=98 [80%] P=0.564
No Nodes Per participant 2.42 2.06 2.26 1.89 P=0.5248
SUVmax 6.76 4.09 6.79 3.60 P=0.9471
Diameter 1.70 0.73 1.69 0.76 P=0.9218
Highest SUVmax 9.22 6.90 8.90 5.50 P=0.7212
Maximum Diameter 2.27 1.30 2.20 1.34 P=0.7073
Total n=114 [89%] n=111 [91%] v2: P=0.613
No Nodes Per participant 5.57 4.74 4.93 4.54 P=0.2739
SUVmax 3.57 2.44 3.51 2.54 P=0.8676
Diameter 0.88 0.49 0.83 0.48 P=0.4424
Highest SUVmax 9.67 7.05 9.44 5.89 P=0.7911
Maximum Diameter 2.48 1.78 2.32 1.41 P=0.4488
Abbreviations: SD, standard deviation; SUV, standardized uptake value.
a There were no significant differences seen between the number of nodes per participant, maximum SUV uptake, and maximum diameter of the visual-
ized lymph nodes between HIV-positive and HIV-negative participants.
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associated with a 2.7-fold increase in the odds of the participant
being HIV-positive (P= .001), with HIV-positive participants
having a maximum of 3 axillary nodes and a mean of 0.37
nodes, and HIV-negative participants having a maximum of 2
and a mean of 0.08 nodes (P= .001). Symmetry was not associ-
ated with HIV status (symmetry of axillary nodes in HIV-positive
participants, 17 out of 29, 59%; symmetry of axillary nodes in
HIV-negative participants, 3 out of 7, 43%; P= .451).
Inguinal Nodes (Known to Be Positive in Chronic HIV
Infection). The SUVmax and size were not predictors of HIV sta-
tus in the inguinal lymph nodes. However the number of inguinal
lymph nodes and the symmetry was significantly associated with
HIV infection (symmetry of inguinal nodes seen in HIV-positive
participants, 11 out of 21, 52%; symmetry of inguinal nodes seen
in HIV-negative participants, 2 out of 14, 14%; P= .022). The
number of nodes was a significant predictor of HIV status
(P= .047; 95%CI, 1.01–2.83; OR, 1.69) in a logistic regression
and there was a significant difference in the mean number of
nodes between the 2 groups with a mean of 0.6 nodes in the HIV-
positive participants and a mean of 0.3 nodes in the HIV-nega-
tive participants (t-test: P= .0417).
Colic or Mesenteric Nodes (Known to Be Positive in Late-Stage
HIV Infection). There were no significant associations between
HIV status and the number, symmetry, SUVmax, or size of the
colic, paracolic, or mesenteric lymph nodes.
Nodes Involved in Draining the Cervix. Nodes included in this
analysis are paracervical, parametrial, presacral, sacral, external
and internal iliac, common iliac, hypogastric, and para-aortic
nodes. There were no significant relationships between HIV sta-
tus and SUVmax, size, number, or symmetry in these nodes.
Online supplemental Images 6a and 6b are of the HIV-positive
(6a) and HIV-negative (6b) participants with the highest number
of lymph nodes visualized in the pelvic region.
Additional Findings. In our sample, aortopulmonary nodes
were significantly (P= .0096) more frequent in HIV-negative par-
ticipants (mean, 0.15; SD, 0.454; 95%CI, 0.01–0.08) than in HIV-
positive participants (mean, 0.05; SD, 0.217; 95%CI, 0.08–0.22),
and abdominal caval nodes had higher SUVmax in HIV-negative
participants (mean, 7.941) than in HIV-positive participants
(mean, 5.685; P= .0430). Online supplemental Image 7 is of the
HIV-positive participant with the largest node (3.1 cm) and the
node with the highest SUV (24.38) in the head and neck region
and in the thorax (SUV: 21.77; size: chain of>14 cm).
DISCUSSION
The uniformity in presentation of nodes draining the cervix in
HIV-positive and HIV-negative LACC participants confirms that
visualization of these nodes on 18F-FDG PET/CT scans may be
attributed to malignancy rather than HIV status of the partici-
pants in our sample. Overall there are some novel differences
between the visualization of lymph nodes in HIV-positive and
HIV-negative participants in our study, which may be of use in
deciding the likely cause of the increased FDG uptake in some
patients; however, the overall pattern of presentation and the
nodal characteristics are similar between the two groups.
There is a significant association between higher SUVmax
and larger lymph node diameter visualized in 18F-FDG PET/CT.
SUVmax and node size were consistently higher in the pelvis and
abdomen than in the thorax and head and neck regions regard-
less of the HIV status. The number of nodes visualized in the pel-
vis was higher that than in any other region. These findings are
all in line with the literature and the expected route of metastatic
spread of cervical cancer (11-13). In a report by Iyengar et al.
(22) on the FDG uptake in 12 patients with acute HIV infection
and 11 patients with mid/chronic HIV infection, all patients pre-
sented with an FDG uptake that was greater in the cervical and
axillary lymph nodes than in the inguinal and iliac chains. The
patients in their study were however not all on ART, and there
was a significant correlation between FDG PET signal and viral
load (22). In our sample of HIV-positive cervical cancer partici-
pants, most of whom were on ART, the highest SUVmax was still
seen in the pelvis and abdomen.
There is a risk of underestimating the extent of lymph node
involvement in HIV-positive participants if the increased FDG
uptake of a node is incorrectly attributed to HIV infection. We
were therefore specifically interested in the differences in lymph
node presentation between HIV-positive and HIV-negative par-
ticipants in our sample.
The visualization of head and neck nodes is frequently
cited in the literature as being associated with acute HIV infec-
tion (18-20, 22). The majority of participants in our study
(82%) were on ART for >6 months, and the majority of these
not on ART were aware of their HIV-status and were not likely
to be in acute stages of HIV infection. The majority of our par-
ticipants also had a CD4 count >200 cells/mL. Although more
head and neck lymph nodes were visualized in the HIV-posi-
tive participants in our sample, differences in the number of
head and neck nodes visualized between HIV-positive and
HIV-negative participants were not significant. However, >4
nodes in the head and neck region were more likely to be seen
in HIV-positive patients. Further histological evaluation of
nodes in this region for malignancy in HIV-positive patients
may therefore still be warranted.
Kidd et al. (6), reported that 53% of 234 patients with LACC
presented with FDG-avid lymph nodes on 18F-FDG PET/CT scans,
and in that sample, the nodes were visualized as high as the supra-
clavicular region. Our sample only included participants in FIGO
stages IIB to IIIB (staged clinically), and the number of participants
with FDG-avid nodes in our study was considerably higher (90%),
likely because of the higher proportion of our participants with
more advanced stages of disease. We also saw increased FDG
uptake in the supraclavicular nodes that are known to be potential
sites of metastatic spread in patients with cervical cancer. In our
sample however, the number of supraclavicular nodes visualized
was significantly higher in the HIV-positive participants despite
the management of the HIV infection with ART. Based on these
findings, further assessment of supraclavicular nodes visualized in
HIV-positive cervical cancer patients to rule out HIV infection as a
cause of the increased FDG-uptake may be warranted.
Although axillary nodes were significantly associated with
HIV infection in our sample, the relationship was not exclusive,
with 6% of HIV-negative participants presenting with FDG-avid
axillary nodes. The spread to axillary nodes can therefore not be
conclusively excluded in HIV-positive immunocompetent patients
with chronic HIV-infection who are on ART and have a CD4
count>200 cells/mL.
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Symmetrical inguinal lymph nodes are more likely to be
visualized in HIV-positive participants, even if their HIV infection
is managed. This is in line with the literature that has found ingui-
nal nodes to be FDG-avid during chronic HIV infection.
In HIV-positive participants, larger nodes were associated
with lower CD4 counts and the only difference in size between
HIV-positive and -negative participants was seen in the abdo-
men, where larger nodes were more common in HIV-positive
participants. The literature shows a significant association
between CD4 count and SUVmax (16, 17); however, we did not
see the same significant association. The majority of our partici-
pants had a CD4 count >200 cells/mL and the association may
therefore be more relevant to patients with a CD4 count<200
cells/mL. Based on our results it appears that the SUVmax in
immunocompetent patients is a reliable measurement of meta-
bolic activity in potentially metastatic nodes.
Fewer participants in this studywere in the late stage of HIV infec-
tion, with only 7.8% of HIV-positive participants presenting with a
CD4 count<200 cells/mL. The lack of colic or mesenteric nodes visual-
ized in our sample is therefore in line with the literature (19).
Limitations
Although histology remains the gold standard for a definitive diag-
nosis of the nature of lymph node pathology, histological sampling
of all PET-positive lymph nodes is not always ethically feasible.
CONCLUSION
Our results indicated that 18F-FDG PET/CT is a reliable staging
method for LACC regardless of the HIV status, provided the
patients are not in acute stages of HIV infection, have a CD4 count
>200 cells/mL, and/or are on ART. The results of this study are
clinically relevant, as this may be of assistance in determining
which lymph nodes visualized on 18F-FDG PET/CT are likely to be
due to metastatic spread in HIV-positive patients with LACC, and
in preventing understaging of HIV-positive LACC patients.
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